• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

MGC Pharmaceuticals Acquires Medicinal Cannabis Clinic (ASX:MXC)

Like 0

By Ryan Clarkson-Ledward, Monday, 20 July 2020

It’s been a while since pot stocks have made headlines. The industry as a whole has been fairly quiet lately. Largely overshadowed by the ongoing pandemic and its fallout. That hasn’t stopped MGC Pharmaceuticals Ltd [ASX:MXC] from their plans though.

It’s been a while since pot stocks have made headlines.

The industry as a whole has been fairly quiet lately. Largely overshadowed by the ongoing pandemic and its fallout.

That hasn’t stopped MGC Pharmaceuticals Ltd [ASX:MXC] from their plans though.

The medicinal cannabis specialist is trading 4.17% at time of writing. The MXC share price rising slightly after acquiring Medicinal Cannabis Clinic (MCC), an Australian business that offers cannabis-based treatments to patients.

And for MGC, this could be their ticket into the local market…

More patients, more drugs

Based out of Europe, MGC only just acquired its import license on 8 July.

Meaning up until just under three weeks ago, they couldn’t even get their products into the country. Namely, their CannEpil and CogniCann drugs, used to treat epilepsy and dementia/Alzheimer’s respectively.

Now though, not only can they import these products, but they also have a wholly-owned distribution network. Utilising MCC’s patient and professional ties to generate awareness and sales of both drugs.

As MGC co-founder, Roby Zomer comments:

‘The acquisition of Medicinal Cannabis Clinics’ assets is an important part of our strategy to grow our distribution network and direct supply chain capabilities in both Australia and Internationally.

‘Importantly, with the acquisition of MCC’s assets, MGC Pharma will be well on the way to achieving our cashflow breakeven targets.

‘We look forward to integrating MCC’s high quality network of clinics.’

No doubt, MGC will be hoping this is just the first of many deals to come. Perhaps even expanding MCC into a multi-clinic business. Reaching new markets across the country.

For now, they’re starting small and building up.

Just like the broader industry for that matter.

Because we have to remember, cannabis is still very much an industry in its infancy. At least, it is in Australia.

Pot stock potential

For long-time MGC investors, today’s news is unlikely to inspire any great confidence.

Like many pot stocks, the company has been in a steady decline since the 2018 highs. Afflicted by ongoing red-tape and pessimism surrounding cannabis.

It’s a sector that still has a long road ahead of it. One that has been very rocky so far.

However, that doesn’t mean you should count pot stocks out just yet.

Because while times are tough now, the potential to turn things around is still very possible.

All it takes is one policy change, or development to bring back interest. A trigger that could put pot stocks back on the map big time.

The upcoming New Zealand referendum, for example, can’t be ignored. A vote that could be the catalyst for a cannabis revival. That is, if the Kiwis vote in favour of it.

One way or another, the push to legalise cannabis — both medicinally and recreationally — isn’t going away. It is likely just a matter of time before the world comes around.

For now it’s up to investors to decide if they’re willing to take that risk.

Obviously, for some, it is a risk that is too big to bear. And that’s perfectly reasonable.

If you’re looking for small-cap opportunities with less speculation, then we’ve got you covered.

Check out our ‘high-value small-cap’ report, including four stock picks to get you started, right here.

Regards,

Ryan Clarkson-Ledward,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Ryan Clarkson-Ledward

Ryan’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • America on a War Footing: Implications as US Mineral Strategy Turns to Africa
    By James Cooper

    Geologist James Cooper examines the potential implications of America’s heavy focus on West Africa. Why is the US becoming deeply involved here? And what could the consequences be?

  • The biggest quarter on record for this share
    By Callum Newman

    We can see why the stock market didn’t react much to the RBA holding rates steady last meeting. Everyone expects rates to go down. It’s just a question of when. Fixed rate loans, and refinancings, are withering away as the market positions for more rate cuts. This is what you and I want to see as investors…

  • The US$2 Trillion Stablecoin Tsunami
    By Charlie Ormond

    These developments could transform the US$250 billion stablecoin market into a US$2 trillion juggernaut within years.

Primary Sidebar

Latest Articles

  • America on a War Footing: Implications as US Mineral Strategy Turns to Africa
  • The biggest quarter on record for this share
  • The US$2 Trillion Stablecoin Tsunami
  • Trump Sparks Rare Earth Rally
  • Copper Breaks Out: Are You Positioned?

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988